Metabolic Profiles of Clinical Isolates of Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis: A Metabolomics-Based Study
Li Wang,Ruoyan Ying,Yidian Liu,Qin Sun,Wei Sha
DOI: https://doi.org/10.2147/IDR.S405987
2023-05-03
Infection and Drug Resistance
Abstract:Li Wang, 1, 2 Ruoyan Ying, 3 Yidian Liu, 1, 2 Qin Sun, 1– 3 Wei Sha 1– 3 1 Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China; 2 Department of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China; 3 Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China Correspondence: Wei Sha; Qin Sun, Email ; Background: Mycobacterium tuberculosis (MTB) is a global and highly deleterious pathogen that creates an enormous pressure on global public health. Although several effective drugs have been used to treat tuberculosis, the emergence of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) has further increased the public health burden. The aim of this study was to describe in depth the metabolic changes in clinical isolates of drug-susceptible Mycobacterium tuberculosis (DS-MTB) and MDR-MTB and to provide clues to the mechanisms of drug resistance based on metabolic pathways. Methods: Based on the minimum inhibition concentration (MIC) of multiple anti-tuberculosis drugs, two clinical isolates were selected, one DS-MTB isolate (isoniazid MIC=0.06 mg/L, rifampin MIC=0.25 mg/L) and one MDR-MTB isolate (isoniazid MIC=4 mg/L, rifampin MIC=8 mg/L). Through high-throughput metabolomics, the metabolic profiles of the DS-MTB isolate and the MDR-MTB isolate and their cultured supernatants were revealed. Results: Compared with the DS-MTB isolate, 128 metabolites were significantly altered in the MDR-MTB isolate and 66 metabolites were significantly altered in the cultured supernatant. The differential metabolites were significantly enriched in pyrimidine metabolism, purine metabolism, nicotinate and nicotinamide metabolism, arginine acid metabolism, and phenylalanine metabolism. Furthermore, metabolomics analysis of the bacterial cultured supernatants showed a significant increase in 10 amino acids (L-citrulline, L-glutamic acid, L-aspartic acid, L-norleucine, L-phenylalanine, L-methionine, L-tyrosine, D-tryptophan, valylproline, and D-methionine) and a significant decrease in 2 amino acids (L-lysine and L-arginine) in MDR-MTB isolate. Conclusion: The present study provided a metabolite alteration profile as well as a cultured supernatant metabolite alteration profile of MDR-MTB clinical isolate, providing clues to the potential metabolic pathways and mechanisms of multidrug resistance. Keywords: Mycobacterium tuberculosis , multidrug-resistant Mycobacterium tuberculosis , drug-susceptible Mycobacterium tuberculosis , metabolomics, metabolic pathway Tuberculosis (TB) is an ancient human disease caused by MTB, but its global epidemiological trajectory still presents a rather grim picture. 1 TB is ranked as a major contributor to the global disease burden, causing more than one million deaths each year. 2 There are about a quarter of the world's population infected with MTB, equivalent to about 2 billion people. 3 Globally in 2020, there were an estimated 1.3 million deaths among HIV-negative people, and an additional 214000 deaths among HIV-positive people. 3 Concurrently, the treatment of TB has become more difficult and challenging with the emergence of drug-resistant variants. 4 Resistance to the first-line antituberculosis drugs isoniazid and rifampicin is of greatest concern. And resistance to at least both drugs is defined as multidrug-resistant tuberculosis (MDR-TB). Globally in 2020, 71% (2.1/3.0 million) of patients diagnosed with pulmonary tuberculosis were tested for rifampicin resistance, identifying 132,222 cases of MDR-TB or rifampicin-resistant tuberculosis (RR-TB). 3 And the treatment of MDR/RR-TB is not very promising, with a treatment success rate of only 59% for MDR/RR-TB in 2018. 3 Metabolomics is key to the study of all life-critical metabolites in living organisms and can contribute to the screening of biomarkers, as well as to revealing regulatory pathways. 5 Metabolomics focuses on global or system-level study of small molecules in specific biological systems and is therefore a promising research tool for the study of cell physiology, and biochemistry within pathogenic microorganisms. Metabolomic studies on MTB are still at an early stage. 6 Currently, Xiao et al 7 analyzed MTB stain H37Rv using non-targeted metabolomics and showed that H37Rv specifically induced tryptophan metabolism in human macrophages. Through widely -Abstract Truncated-
pharmacology & pharmacy,infectious diseases